ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) SVP Ori Gutwerg sold 2,772 shares of the stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $79.50, for a total transaction of $220,374.00. Following the transaction, the senior vice president directly owned 78,696 shares in the company, valued at $6,256,332. The trade was a 3.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.
Ori Gutwerg also recently made the following trade(s):
- On Tuesday, March 3rd, Ori Gutwerg sold 2,060 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $76.50, for a total transaction of $157,590.00.
ANI Pharmaceuticals Stock Up 1.7%
ANI Pharmaceuticals stock traded up $1.38 during mid-day trading on Wednesday, hitting $80.88. 308,836 shares of the company’s stock were exchanged, compared to its average volume of 412,504. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. The stock has a market cap of $1.81 billion, a P/E ratio of 20.48 and a beta of 0.46. ANI Pharmaceuticals, Inc. has a 1-year low of $56.71 and a 1-year high of $99.50. The stock has a 50 day moving average of $77.08 and a two-hundred day moving average of $80.70.
Institutional Investors Weigh In On ANI Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the business. Divisadero Street Capital Management LP acquired a new stake in shares of ANI Pharmaceuticals in the third quarter valued at about $21,454,000. Campbell & CO Investment Adviser LLC acquired a new stake in shares of ANI Pharmaceuticals in the third quarter valued at about $1,597,000. Apis Capital Advisors LLC grew its position in shares of ANI Pharmaceuticals by 28.1% in the third quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock valued at $15,022,000 after purchasing an additional 36,000 shares during the last quarter. Decker Retirement Planning Inc. grew its position in shares of ANI Pharmaceuticals by 76,862.5% in the third quarter. Decker Retirement Planning Inc. now owns 36,942 shares of the specialty pharmaceutical company’s stock valued at $3,384,000 after purchasing an additional 36,894 shares during the last quarter. Finally, SG Americas Securities LLC grew its position in ANI Pharmaceuticals by 791.1% during the third quarter. SG Americas Securities LLC now owns 22,847 shares of the specialty pharmaceutical company’s stock worth $2,093,000 after buying an additional 20,283 shares in the last quarter. 76.05% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
ANIP has been the topic of several analyst reports. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. Guggenheim raised their price target on ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Finally, Zacks Research raised ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 15th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $107.33.
View Our Latest Research Report on ANIP
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Read More
- Five stocks we like better than ANI Pharmaceuticals
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
